The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Sinovac Biotech Ltd

NEW YORK--()--The Klein Law Firm announces the commencement of an investigation of Sinovac Biotech Ltd (NASDAQ: SVA) concerning possible violations of federal securities laws.

On December 21, 2016, an article published by SeekingAlpha.com revealed that Sinovac's Chairman and Chief Executive Officer, Weidong Yin, paid bribes to the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration and his wife, to help advance drug applications and evaluations. Sinovac later announced on May 16, 2017 that the Securities Exchange Commission is investigating the Company for alleged bribery mentioned in SeekingAlpha's article, and that Sinovac would not be able to file its annual financial results on time.

If you suffered a loss in Sinovac and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/SVA-Info-Request-Form-172.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

The Klein Law Firm
Joseph Klein, Esq., 212-616-4899
Fax: 347-558-9665
www.kleinstocklaw.com

Release Summary

The Klein Law Firm announces the commencement of an investigation of Sinovac Biotech Ltd

Contacts

The Klein Law Firm
Joseph Klein, Esq., 212-616-4899
Fax: 347-558-9665
www.kleinstocklaw.com